A New Clinical Trial – Apoptone

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) has announced a new phase I/II clinical trial of Apoptone (HE3235) for late stage prostate cancer. Howard Scher, M.D., Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center said "The preclinical data generated to date suggest that Apoptone may offer a unique therapeutic approach to late-stage prostate cancer where [...]